Table 2.
Frequency of commonly detected driver mutations between lung, breast, and melanoma primaries for the long-term survivors.
| Molecular Characteristics | Long-Term Survivors |
|---|---|
| Lung primary | (n = 51) |
| EGFR mutation | 21 (41%) |
| ALK rearrangement | 4 (8%) |
| EGFR/ALK- | 21 (41%) |
| Unknown | 5 (10%) |
| Breast primary | (n = 24) |
| ER/PR +/Her 2+ | 6 (25%) |
| ER/PR+/Her 2- | 10 (42%) |
| ER/PR-/Her 2+ | 6 (25%) |
| Triple-negative | 2 (8%) |
| Unknown | 0 (0%) |
| Melanoma | (n = 5) |
| BRAF+ | 0 (0%) |
| BRAF- | 2 (40%) |
| Unknown | 3 (60%) |
EGFR: Epidermal growth factor receptor; ALK: Anaplastic lymphoma kinase; ER: Estrogen receptor; PR: Progesterone receptor; Her 2: Human epidermal growth factor receptor 2.